{
  "docId": "019de071-41d7-735b-bdce-76898f0847d2",
  "docSlug": "eaafde7daeccaea38d88b7264ade91c5",
  "documentTitle": "Erasca | IPO Presentation Deck | 46 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 46,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "appendix_data",
  "function": "other",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/3",
  "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2",
  "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json",
  "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.72,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "table",
      "text": "Issuer (Exchange / Ticker) Erasca, Inc. (Nasdaq / ERAS) Base Offering Size 17,500,000 shares (100% primary) Option to Purchase Additional Shares 2,625,000 shares (100% primary, 15% of the base shares) Price Range $14.00 - $16.00 per share Lock-up 180 days for the Company, directors, executive officers, and substantially all security holders Use of Proceeds The Company intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and investments, to: (i) fund the clinical development of ERAS-007 in its Phase 1b/2 HERKULES series of clinical trials, including through data readout(s) for one or multiple of such HERKULES trials, (ii) fund the clinical development of ERAS-601, including through a data readout for the FLAGSHP-1 Phase 1 trial, (iii) fund the ongoing discovery and development of its other current RAS/MAPK pathway-focused pipeline programs, including to advance one or multiple product candidate(s) into the clinic; and (iv) the remainder for working capital and general corporate purposes. Bookrunners J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, Guggenheim Securities Stabilization Agent J.P. Morgan Expected Pricing Date Thursday, July 15th, 2021",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7584c2fa-7f96-4508-b23b-e1f681b2eca1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Offering summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab7ebc39-64f2-454b-9f16-57aab7d261c3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}